Compare ClearPoint Neuro Inc (CLPT) vs Sunrun Inc (RUN) Price & Performance

ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.

Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.

Sunrun (RUN) trades at $12.41, down 0.48% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong profitability with a 17.88% net income margin and ROE of 19.06%, while valuation metrics like P/E of 6 and P/B of 0.91 suggest potential undervaluation. Recent news highlights a major partnership with Tesla and Renew Home for a 16-gigawatt virtual power plant, driving investor interest in grid-support initiatives tied to AI data center demand.

The stock presents a mixed outlook: analyst consensus is strongly bullish with a $17.09 price target (62% buy ratings), but negative operating cash flow and high debt-to-asset ratio of 70.76% pose risks. Growth catalysts include expanding revenue and margin trends, though execution on new ventures and macroeconomic pressures remain key watchpoints for investors.